Ted Jadick places new Assertio Therapeutics Board of Directors Member
Assertio Therapeutics Announces Appointment of Dr. David Wheadon to its Board of Directors
September 30, 2019
LAKE FOREST, Ill., Sept. 30, 2019 (GLOBE NEWSWIRE) — Assertio Therapeutics, Inc. (NASDAQ: ASRT) announced today that Dr. David Wheadon
has been appointed to the Company’s Board of Directors. Dr. Wheadon is a former senior executive of AstraZeneca plc.
“David is a globally recognized leader in healthcare and we are thrilled to have him join our Board of Directors,” said Arthur Higgins, President and
CEO of Assertio. “David’s perspectives, both as a physician and as an executive with significant and broad industry expertise, will add further depth
and breadth to our Board.”
“I am excited to serve on Assertio’s Board and contribute to its ongoing transformation into a leading diversified biopharmaceutical company,” said Dr.
Wheadon.
Dr. Wheadon is a former senior executive of AstraZeneca plc, having recently retired as Senior Vice President, Global Regulatory Affairs, Patient
Safety and Quality Assurance. Dr. Wheadon has held many leadership roles in the healthcare sector, including: Executive Vice President, Research
and Advocacy at the Juvenile Diabetes Research Foundation; Senior Vice President, Scientific and Regulatory Affairs at PhRMA; Senior Vice
President of Global Pharmaceutical Regulatory and Medical Sciences at Abbott Laboratories; Senior Vice President of U.S. Regulatory Affairs at
GlaxoSmithKline Pharmaceuticals; Vice President and Director CNS/GI Clinical Research at SmithKline Beecham Pharmaceuticals; and Clinical
Research Physician at Eli Lilly and Company. Dr. Wheadon has been integral to the successful development and approval of several important drugs
for central nervous system diseases, diabetes, gastrointestinal disorders and diseases in other therapeutic areas.
Dr. Wheadon holds a M.D. from Johns Hopkins University School of Medicine and an A.B. in Biology from Harvard University. He completed his
postdoctoral training in Psychiatry at Tufts/New England Medical Center in Boston, Massachusetts.
About Assertio Therapeutics, Inc.
Assertio Therapeutics is committed to providing responsible solutions to advance patient care in the Company’s core areas of neurology, orphan and
specialty medicines. Assertio currently markets three FDA-approved products and continues to identify, license and develop new products that offer
enhanced options for patients that may be underserved by existing therapies. To learn more about Assertio, visit www.assertiotx.com.
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995
This news release contains forward-looking statements. These statements involve inherent risks and uncertainties that could cause actual results to
differ materially from those projected or anticipated, including risks outlined in the Company’s public filings with the Securities and Exchange
Commission, including the Company’s most recent annual report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. All information
provided in this news release speaks as of the date hereof. Except as otherwise required by law, the Company undertakes no obligation to update or
revise its forward-looking statements.
Investor and Media Contact:
John B. Thomas
SVP, Investor Relations and Corporate Communications
jthomas@assertiotx.com